Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE
Date Title  
Friday, November 10, 2017 Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting
Thursday, November 9, 2017 Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors
Upcoming and Recent Events > MORE
Date Title  
Saturday, November 11, 2017
5:45 PM ET
Five Prime Therapeutics Conference Call
Supporting Materials
PDF View Presentation  2.6 MB   Add to Briefcase
Wednesday, November 8, 2017
8:00 AM ET
Five Prime Therapeutics Conference Call
Supporting Materials
PDF View Presentation 921.4 KB   Add to Briefcase
Monday, November 6, 2017
4:30 PM ET
Five Prime Therapeutics, Inc. 2017 Q3 Quarterly Earnings Call
Supporting Materials
PDF View Presentation 732.1 KB   Add to Briefcase

FPRX (Common Stock)

Change (%)

Data as of 4:00 PM ET on Friday, November 17, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.